Načítá se...
Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib
BACKGROUND: Crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with anaplastic lymphoma kinase-positive (alk+) non-small cell lung cancer (nsclc), but little information is available on its use and outcomes in real-world settings. We therefore assessed treatment p...
Uloženo v:
| Vydáno v: | Curr Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Multimed Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5832290/ https://ncbi.nlm.nih.gov/pubmed/29507494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3723 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|